MetaVia Inc.
MTVA
Kedudukan dalam Saham
#32861
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Harga Saham
$1.30
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$8.53M
Perubahan (1 hari)
-5.47%
Perubahan (1 tahun)
-20.55%
Negara
US
Perdagangan MetaVia Inc. (MTVA)
Kategori
Healthcare
EPS untuk MetaVia Inc. (MTVA)
EPS setakat June 2026 TTM: $-8.42
Menurut laporan kewangan terkini dan harga saham MetaVia Inc., EPS semasa syarikat (TTM) adalah $-8.42. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-2.46 peningkatan berbanding EPS tahun 2022 iaitu $-19.01.
Sejarah EPS untuk MetaVia Inc. dari 2014 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-8.42 | 136.52% |
| 2024 | $-3.56 | 44.72% |
| 2023 | $-2.46 | -87.06% |
| 2022 | $-19.01 | -87.96% |
| 2021 | $-157.85 | -64.06% |
| 2020 | $-439.20 | -57.38% |
| 2019 | $-1.03K | 517.81% |
| 2018 | $-166.80 | -93.11% |
| 2017 | $-2.42K | 28.59% |
| 2016 | $-1.88K | 47.42% |
| 2015 | $-1.28K | 2,721.85% |
| 2014 | $-45.27 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -305.70% |
US
|
|
| $-7.98 | -5.23% |
US
|
|
| $-5.29 | -37.17% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -429.45% |
NL
|
